Ignite Creation Date:
2024-05-05 @ 7:25 PM
Last Modification Date:
2024-10-26 @ 9:48 AM
Study NCT ID:
NCT00668291
Status:
COMPLETED
Last Update Posted:
2016-07-06
First Post:
2008-04-25
Brief Title:
Primary Pigmented Nodular Adrenocortical Disease PPNAD and the CARNEY Complex CNC
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Assistance Publique - Hôpitaux de Paris
Study Overview
Official Title:
Assessment of the Clinical Symptoms of the Primary Pigmented Nodular Adrenocortical Disease PPNAD and the CARNEY Complex CNC
Status:
COMPLETED
Status Verified Date:
2016-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EVACARNEY
Brief Summary:
Cohort CNC-PPNAD will be investigated with clinical genetic biological and imaging work-up every year during 3 years Cohort L-MC will be investigated clinically at inclusion and a PERKAR1A genotype will be performed
Detailed Description:
The primary aim is to assess the clinical manifestations of the CARNEY Complex CNC andor the primary pigmented nodular adrenocortical disease PPNAD in patients with CNC isolated PPNAD or carriers of PRKAR1A and PPNAD1 PDE11A4 germline mutation Cohort CNC-PPNAD In this cohort genotypephenotype correlation will be studied A second aim is to determine the frequency of PRKAR1A germline mutation in patients with isolated cardiac myxoma or isolated lentiginosis Cohort L-MC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None